Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Advanced Malignancies
NCT03474640Phase 1Completed
- Sponsor
- Top Alliance Biosciences
- Start
- Feb 2018
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of toripalimab in solid tumor (advanced stage), esophageal carcinoma, Gastric carcinoma (GC) and 5 more (2 arms), sponsored by Top Alliance Biosciences. Primary endpoint: Number of Participants With Treatment-related Adverse Events. Started Feb 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
solid tumor (advanced stage)esophageal carcinomaGastric carcinoma (GC)nasopharyngeal carcinoma (NPC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03474640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474640.